2012 Year in Review: FDA OPDP Warning Letters and Untitled Letters

more+
less-

In 2012, the Center for Drug Evaluation and Research’s (CDER) Office of Prescription Drug Promotion (OPDP) issued a total of 28 enforcement letters to pharmaceutical manufacturers, two fewer than in 2011. Of the 28 letters, three were Warning Letters and 25 were Untitled Letters. Roughly 68 percent (19 letters) of the promotional materials reviewed in the enforcement letters were directed at healthcare professionals, and 5 of OPDP’s enforcement letters were issued regarding drugs with boxed warnings, including one Warning Letter. Only three enforcement letters (11% of all enforcement letters issued) were the result of complaints received through the Bad Ad Program, one of which was a Warning Letter and two of which cited oral statements by sales representatives. Two enforcement letters were issued regarding emerging media —an iPad sales aid and a podcast interview.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  FDA, OPDP, Patient Testimonials, Pharmaceutical, Prescription Drugs, Warning Letters

Published In: Administrative Agency Updates, Communications & Media Updates, Health Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »